



Update on Decapinol in the US and of recent trading statement

14 August 2007, Godalming, UK Sinclair Pharma plc ("Sinclair"), the specialty pharmaceutical company, today provides an update on the commercial status of Decapinol in the US and an adjustment to the trading statement issued on 24th July 2007.

Decapinol in the US

OraPharma, Inc. ("OraPharma"), Sinclair's marketing and distribution partner for Decapinol, in the US has decided to delay the first commercial sale of Decapinol in the United States. OraPharma has decided to explore adding a preservative to the US product in order to make the formulation more robust.

These events do not affect the sale of Decapinol in other jurisdictions.

OraPharma remains committed to Decapinol and to its relationship with Sinclair, and views Decapinol as an important part of their future portfolio. Both parties are collaborating closely and hope to launch the new formulation in the U.S. in 2008.

Update to trading statement

The trading statement issued on 24 July 2007 included approximately £750,000 of revenue that had been invoiced to OraPharma, after production and delivery of the batches intended for launch. As it has now been determined that the launch will be delayed, in the light of the circumstances above, the board of Sinclair has decided not to include this amount in the final results for the year ending 30 June 2007.

Dr Michael Flynn, CEO of Sinclair, commented "We are disappointed by this delay to the final stage of the launch process for the US. However we are confident of OraPharma's continuing commitment to Decapinol and the precautionary measures they are taking in reformulating the product, and we will be working with them to bring the new formulation to the market. It is important to remember that Decapinol in the US represents just one of many revenue streams for Sinclair, and we remain busy with our commercial operations in Europe and with our other flagship products in territories across the globe."

Ends

For further information please contact:

Sinclair Pharma plc

Dr Michael Flynn, CEO
Zoe McDougall, Director of Communications

Tel: +44 (0) 1483 410 600

Capital MS&L

Mary Clark, Halina Kukula

Tel +44 (0)20 7307 5340

Notes to Editors:

About Sinclair Pharma Plc www.sinclairpharma.com

Sinclair Pharma plc is an international specialty pharmaceutical company. It has a growing sales and marketing operation that is already present in France, Italy, UK, Spain and Portugal, and a complementary marketing partner network that spans more than 65 countries.

Sinclair has proven expertise in acquiring or developing commercially attractive and undervalued products, registering these products and bringing them to market within a short timeframe. The



company focuses on niche therapeutic areas and its current portfolio includes products for dermatological conditions and oral health.

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.